Similar Search Results

Bayesian Adaptive Clinical Trials for Anti‐Infective Therapeutics during Epidemic Outbreaks

Chaudhuri, Shomesh - 2020

In the midst of epidemics such as COVID-19, therapeutic candidates are unlikely to be able to complete the usual multiyear clinical trial and regulatory approval process within the course of an outbreak. We apply a Bayesian adaptive patient-centered model--which minimizes the expected harm of...

Persistent link: https://www.econbiz.de/10012481758

Discovering Treatment Effectiveness via Median Treatment Effects—Applications to COVID-19 Clinical Trials

Mullahy, John - 2020

Comparing median outcomes to gauge treatment effectiveness is widespread practice in clinical and other investigations. While common, such difference-in-median characterizations of effectiveness are but one way to summarize how outcome distributions compare. This paper explores properties of...

Persistent link: https://www.econbiz.de/10012482114

Technology Diffusion and Productivity Growth in Health Care

Skinner, Jonathan - 2009

Inefficiency in the U.S. health care system has often been characterized as "flat of the curve" spending providing little or no incremental value. In this paper, we draw on macroeconomic models of diffusion and productivity to better explain the empirical patterns of outcome improvements in...

Persistent link: https://www.econbiz.de/10012463783

Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits

Gaynor, Martin - 2006

Recently, many U.S. employers have adopted less generous prescription drug benefits. In addition, the U.S. began to offer prescription drug insurance to approximately 42 million Medicare beneficiaries in 2006. We use data on individual health insurance claims and benefit data from 1997-2003 to...

Persistent link: https://www.econbiz.de/10012465903

The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality

Lichtenberg, Frank R. - 1996

This paper presents an econometric analysis of the effect of changes in the quantity and type of pharmaceuticals … hospital stays, bed-days, and surgical procedures declined most rapidly for those diagnoses with the greatest increase in the … an increase of 100 prescriptions is associated with 1.48 fewer hospital admissions, 16.3 fewer hospital days, and 3 …

Persistent link: https://www.econbiz.de/10012473446

Effects of Prescription Drug Insurance on Hospitalization and Mortality : Evidence from Medicare Part D

Kaestner, Robert - 2014

We examine whether obtaining prescription drug insurance through the Medicare Part D program affected hospital … Medicare Part D was associated with an 8% decrease in the number of hospital admissions, a 7% decrease in Medicare expenditures …

Persistent link: https://www.econbiz.de/10012458717

Human Capital and Organizational Performance : Evidence from the Healthcare Sector

Bartel, Ann P. - 2011

use detailed longitudinal monthly data on nursing units in the Veterans Administration hospital system to identify how the … human capital (general, hospital-specific and unit or team-specific) of the nursing team on the unit affects patients …

Persistent link: https://www.econbiz.de/10012461185

Consumption Externalities and Diffusion in Pharmaceutical Markets : Antiulcer Drugs

Berndt, Ernst R. - 2000

We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a …

Persistent link: https://www.econbiz.de/10012470978

Creating Markets for New Vaccines Part II : Design Issues

Kremer, Michael - 2000

Several programs have been proposed to improve incentives for research on vaccines for malaria, tuberculosis, and HIV, and to help increase accessibility of vaccines once they are developed. For these programs to spur research, potential vaccine developers must believe that the sponsor will not...

Persistent link: https://www.econbiz.de/10012471044

Creating Markets for New Vaccines Part I : Rationale

Kremer, Michael - 2000

Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to sell enough vaccine at a sufficient price to...

Persistent link: https://www.econbiz.de/10012471045

1
2
3
4
5
6
7
8
9
10
Next
Last